Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants Emergency Use Authorization for Premier Medical At-Home COVID Assay

NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorization for Premier Medical Laboratory Services' Diversified Medical Healthcare SARS-CoV-2 Assay.

The real-time RT-PCR-based test is for the qualitative detection of SARS-CoV-2 nucleic acid in anterior nasal swab specimens that are collected at home using the DoINeedaCOVID19Test.com Self-Collection Kit. The test is also authorized for use with anterior nasal swab specimens that are collected using the FDA-authorized RapidRona Self-Collection Kit.

The Diversified Medical Healthcare assay may only be performed by CLIA-certified laboratories designated by Premier Medical, according to the FDA. It uses the same reagents and procedures as Thermo Fisher Scientific's TaqPath COVID-19 RNase P Combo Kit 2.0, which received EUA from the FDA in mid-2021.

In early 2022, Greenville, South Carolina-based Premier Medical received EUA from the FDA for its PMLS SARS-CoV-2 Assay.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.